EGFR and non-small cell lung carcinoma: In a randomized, Phase III AURA3 clinical trial comparing osimertinib with platinum-based doublet chemotherapy in T790M-positive advanced NSCLC patients pre-treated with EGFR-TKI therapy, osimertinib significantly prolonged the median PFS (10.1 vs 4.4 months, 95% confidence interval [CI] 0.23–0.41; P < 0.001) in overall patients and also in patients with CNS metastases (8.5 vs 4.2 months; 95% CI 0.21–0.49) (Mok et al. 2017).